{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:56Z","timestamp":1764510356248,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.jaci.2009.02.003","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T04:40:22Z","timestamp":1236746422000},"page":"687-688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Assessing anaphylactic risk? Consider mast cell clonality"],"prefix":"10.1016","volume":"123","author":[{"given":"Dean D.","family":"Metcalfe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2009.02.003_bib1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cells disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2009.02.003_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF01533368","article-title":"Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis","volume":"14","author":"Schwartz","year":"1994","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(00)03647-3","article-title":"Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings","volume":"357","author":"Ludolph-Hauser","year":"2001","journal-title":"Lancet"},{"issue":"1 Suppl","key":"10.1016\/j.jaci.2009.02.003_bib5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jaci.2007.05.001","article-title":"Risk assessment in anaphylaxis: current and future approaches","volume":"120","author":"Simons","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib6","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The \u03b1 form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2009.02.003_bib7","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1016\/j.jaci.2009.02.003_bib8","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2009.02.003_bib10","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2009.02.003_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cellsig.2007.10.013","article-title":"Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL\/LAB\/LAT2 allows flexibility in its scaffolding function in mast cells","volume":"20","author":"Iwaki","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.jaci.2009.02.003_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis","volume":"121","author":"Gonzalez de Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2009.02.003_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2009.02.003_bib15","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.170.7.3835","article-title":"IL-4 exacerbates anaphylaxis","volume":"170","author":"Strait","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.coi.2008.09.005","article-title":"New concepts in chronic urticaria","volume":"20","author":"Vonakis","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/ACI.0b013e3283036a90","article-title":"Understanding the mechanisms of anaphylaxis","volume":"8","author":"Peavy","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/jpet.107.125237","article-title":"Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation","volume":"324","author":"Jensen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2009.02.003_bib19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2009.02.003_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11882-009-0010-9","article-title":"The problem of anaphylaxis and mastocytosis","volume":"9","author":"M\u00fcller","year":"2009","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674909002309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674909002309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:14:30Z","timestamp":1758788070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674909002309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0091674909002309"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2009.02.003","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing anaphylactic risk? Consider mast cell clonality","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2009.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}